Technical analysis of Mirum Pharmaceuticals, Inc. (MIRM): price and volume charts, candlestick patterns, moving averages (SMA, EMA), RSI, MACD, ADX and Bollinger Bands. Identify momentum, trend direction and potential entry/exit zones.
Mirum Pharmaceuticals, Inc. is a biopharmaceutical firm dedicated to discovering and commercializing groundbreaking therapies for serious rare and orphan conditions. Its lead experimental drug, LIVMARLI, an oral treatment, is currently undergoing trials for progressive familial intrahepatic cholestasis (PFIC), Alagille syndrome, and biliary atresia.
Price Performance
| 1 month | -2.47% |
| 3 months | -8.17% |
| Year-to-date | +24.54% |
| 1 year | +34.51% |
| 3 years | +206.38% |
| 5 years | +444.12% |
52-Week Range
| 52-week High | $130.00 |
| 52-week Low | $63.23 |
| Avg Volume (90d) | 839K |
Technical Indicators
| SMA 50 | $105.57 |
| SMA 200 | $96.99 |
| Beta | 0.52 |
| 30-day Volatility (annualised) | 48.7% |
| Price vs SMA 50 | -6.8% |
| Price vs SMA 200 | +1.4% |
Monthly Close (12 months)
| Month | Close | Change |
|---|
| 2025-10 | $72.65 | |
| 2025-11 | $73.05 | +0.6% |
| 2025-12 | $78.99 | +8.1% |
| 2026-01 | $103.22 | +30.7% |
| 2026-02 | $92.29 | -10.6% |
| 2026-03 | $92.38 | +0.1% |
| 2026-04 | $97.31 | +5.3% |
| 2026-05 | $101.50 | +4.3% |
| 2026-06 | $117.07 | +15.3% |
| 2026-07 | $105.95 | -9.5% |
| 2026-08 | $98.05 | -7.5% |
| 2026-09 | $98.38 | +0.3% |
Upcoming Earnings
| Date | EPS Est. | Revenue Est. |
|---|
| 2026-09-14 | $-2.53 | |
| 2026-09-14 | | |
| 2026-09-14 | $-0.26 | $14M |
| 2026-09-14 | | |
| 2026-09-14 | | $1M |
| 2026-09-14 | | |
Price
| Price | $97.37 |
| Market Cap | $5.9B |
| Exchange | NASDAQ |
| Country | US |
Valuation Ratios
| Price / Book | -565.87 |
| EV / EBITDA | -7.92 |
| Dividend Yield | 0.00% |
Financial Health
| Debt / Equity | -72.97 |
| Current Ratio | 2.86 |
| Piotroski F-Score | 6 |
| Altman Z-Score | 4.42 |